社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
点赞
点赞
回复
1
收藏
编组 21备份 2
分享
矩形
一路走来cd
01-08
修复行情是什么?
是估值的提升?还是业绩的增长
# 创新药利好不断!还有进场机会吗?
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
形状备份
点赞
举报
登录后可参与评论
评论
(1)
推荐
最新
RonaldNixon
·
01-08
估值修复更常见,业绩增长是基础。
回复
回复
点赞
点赞
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":519703737844232,"tweetId":"519703737844232","gmtCreate":1767855916107,"gmtModify":1767855918718,"author":{"id":3459462368857793,"idStr":"3459462368857793","authorId":3459462368857793,"authorIdStr":"3459462368857793","name":"一路走来cd","avatar":"https://static.tigerbbs.com/be085af43e85927a88d1e952e6e9afec","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.01","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":73,"starInvestorFlag":false},"themes":[{"themeId":"5295300d7a5d43469f7e004a8a52759a","categoryId":"d316d8bd4a714fab9ea15fd7157c45e7","name":"创新药利好不断!还有进场机会吗?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":5295300d7a5d43469f7e004a8a52759a}&rnconfig={\"headerBarHidden\": true}","description":"创新药板块利好不断,药明康德公布2025年业绩,净利润149亿,同比+41%;荣昌生物与艾伯维签署授权许可协议,最高可获49.5亿美元里程碑付款;当地时间2026年1月12日,第44届摩根大通(JPM)医疗健康年会在旧金山正式启幕。据悉,截至目前,多家中国创新药企确认参会。【在当前行情下,创新药是你看好的板块吗?】","image":"https://static.tigerbbs.com/3b37f036cb04b5c9130f32429f11130a"}],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p>修复行情是什么?</p>\n<p>是估值的提升?还是业绩的增长</p></body></html>","htmlText":"<html><head></head><body><p>修复行情是什么?</p>\n<p>是估值的提升?还是业绩的增长</p></body></html>","text":"修复行情是什么? 是估值的提升?还是业绩的增长","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/519703737844232","repostId":0,"isVote":1,"tweetType":1,"viewCount":372,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":42,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":519522961195320,"commentId":"519522961195320","gmtCreate":1767857914843,"gmtModify":1767872143313,"authorId":9000000000000407,"author":{"id":9000000000000407,"idStr":"9000000000000407","authorId":9000000000000407,"name":"RonaldNixon","avatar":"https://static.tigerbbs.com/bc939ac6fbcb8985885a8a5671929aec","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":519703737844232,"objectIdStr":"519703737844232","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"估值修复更常见,业绩增长是基础。","text":"估值修复更常见,业绩增长是基础。","html":"估值修复更常见,业绩增长是基础。","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"hasMoreComment":true,"orderType":2}